Q4 2023 13F Holders as of 31 Dec 2023
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
171,717,172
-
Number of holders
-
2
-
Total 13F shares, excl. options
-
60,647
-
Shares change
-
-200,783
-
Total reported value, excl. options
-
$675,115
-
Value change
-
-$1,942,317
-
Number of sells
-
-2
-
Price
-
$11.17
Significant Holders of Relay Therapeutics, Inc. - Common Stock, par value $0.0001 per share (RLAY) as of Q4 2023
3 filings reported holding RLAY - Relay Therapeutics, Inc. - Common Stock, par value $0.0001 per share as of Q4 2023.
Relay Therapeutics, Inc. - Common Stock, par value $0.0001 per share (RLAY) has 2 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 60,647 shares
of 171,717,172 outstanding shares and own 0.04% of the company stock.
Largest 10 shareholders include SB INVESTMENT ADVISERS (UK) LTD (27,904,963 shares), VANGUARD GROUP INC (10,650,387 shares), BlackRock Inc. (9,573,423 shares), PRICE T ROWE ASSOCIATES INC /MD/ (8,581,167 shares), Casdin Capital, LLC (7,387,943 shares), JPMORGAN CHASE & CO (6,065,595 shares), Bellevue Group AG (5,936,082 shares), STATE STREET CORP (4,903,578 shares), BVF INC/IL (3,970,045 shares), and ArrowMark Colorado Holdings LLC (3,914,246 shares).
This table shows the top 2 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.